downgraded to Underweight from Equal Weight; firm projects continued weak balance sheet-adjusted production over the next two years
Contrary to SFY's acreage, etc. Aurora's acreage is already well developed for production and transportation:
Aurora"s primary asset is 22,200 net contiguous acres in the prolific Sugarkane Field located in South Texas in the core of the liquids-rich Eagle Ford shale. Aurora ’s Q4/2013 gross
production was 24,678 boe/d (82 % liquids) of predominantly light, high-quality crude oil.
The Sugarkane Field has been largely delineated with infrastructure in place which is expected to
facilitate low-risk future annual production growth . In addition, these assets have significant future reserves upside potential from well downspacing, improving completion techniques and new development targets in additional zones
SFY recently started to focus more on development of it's Eagle Ford acreage.
I'm a very long time holder of SFY bonds (since mid 2010) and stock but sometimes some of the overly bullish posts (which don't take all relevant factors available into account) on this board keep amazing me.
From Briefing in Play Plus
Special Reports (OPTNX) published the Unusual Options Activity and Volatility Tracker, which highlighted stocks that have seen interesting options activity prior to volatility events. LEAP, VRNG, and S are a few of the names we are watching.
Natural gas futures rallied overnight and almost hit $6/MMBtu as forecasters are now expecting frigid weather at the end of February and heading into early March.
I think the market may have turned a bit defense after SM's substantial downward revision of its Eagle Ford fields' performance. That most probably is keeping a lid on SFY for now untill the co reports.
Get used to it. The moment anyone posts anything (even if they are actual facts supplied by others) that may seem negative for sfy he/she gets blasted or gets a lot of thumbs down. Guess the majority of the longs must be hurting bad, are fed-up, or whatever and they start acting like ostriches, stick your head in the sand, don't face potential reality.
talking about multiple ID's. I see the one you are now using was established feb 19, 2014, a couple of days ago. Hey newbie, Welcome to the yahoo mb's.
Vringo announces ZTE's emergency request to stay enforcement of injunction denied by German Appeals Court (4.10 +0.04)
Co announced that the Karlsruhe Court of Appeal has denied an emergency request for stay of the enforcement of a decision granting among other remedies an injunction against ZTE Corp. and its German subsidiary ZTE Deutschland GmbH
The rulings of the District Court are subject to appeal to the Court of Appeals. Pursuant to German law, the question of validity of patents is dealt with in separate proceedings and before different courts. Accordingly, the Mannheim Court did not rule on the validity of the '119 Patent. A corresponding nullity action filed by ZTE against the '119 Patent is currently pending with the German Federal Patents Court.
Hey newbie, you are contradicting yourself. Better double-check your posts before hitting the post button. You are really dumb, aren't you?
Vivus sales disappoint, but shouldn't surprise; Cowen defends VVUS (5.88 -0.87)
Cowen notes Vivus reported net sales of $7.7M for 4Q and $23.7M for the year, numbers that definitely disappoint, but should not really surprise, given the known scripts trends. Their view remains unchanged: Qsymia is a good obesity drug, but it absolutely needs, like all primary care drugs, especially in obesity, very significant commercial support. Given current valuation, they continue to recommend VVUS shares.
Vivus target lowered to $8 at WallachBeth; 4Q results as expected, but partnership elusive (5.88 -0.87)
WallachBeth lowers their VVUS tgt to $8 from $11 following earnings. The comments from the conference call indicated that co was unable to find a partnership with favourable terms. This is disappointing and concerning for two main reasons. One is that only a big pharma co is really equipped for the marketing of obesity drugs. Without the experience and resource of a large pharma co, VVUS would not be able to overcome one of the major hurdles of obesity drugs -- educating the physicians and patients. The other reason is that co will incur a large cash burn without a partner.
that the co willy beat the eps/rev estimates and more importantly will give a very positive guidance re. production growth in 2014 and beyond. That's the most important thing IMHDO.
I hold both the bonds 2016 and stock. Hope this co will start meeting/exceeding street estimates on a consistent basis.